Trial · NCT02542410
Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study
NCT02542410, Phase 2, Completed, Boston Children's Hospital; results first posted 2020-02-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study. Trials, record NCT02542410. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02542410
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study
- NCT number
- NCT02542410
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 10 participants, actual
- Lead sponsor
- Boston Children's Hospital
- Conditions
- Endometriosis
- Interventions
- Cabergoline, Norethindrone acetate
- First posted
- 2015-09-07
- Last updated
- 2020-02-05
- Results first posted
- 2020-02-05
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Score in Worst Pain Over the Last Month | Baseline, 6 months | visual analog scale, minimum=0 and maximum=10 Higher numbers are a worse outcome Outcome measures is calculated as the value at 6 months minus value at baseline. |
| Secondary | Changes in Pain Interference Scores | Baseline, 6 months | Brief Pain Inventory Interference subscale is a 7-item self-report measure, designed to assess the extent to which pain interferes with various components of functioning, including physical and emotional functioning and sleep.The items in this scale can be grouped into those that assess physical functioning (general activity; walking ability; normal work, including both work outside the home and housework), those that assess emotional functioning (mood; relations with people; enjoyment of life), and a single item that assess the extent to which pain interferes with sleep. The arithmetic mean of the seven interference items is used as a measure of pain interference (i.e., how much a participant's pain interferes with her ability to complete activities of daily living and functioning). The score on the pain interference subscale ranges from 0-70. Higher scores are worse outcomes. Outcome measure calculated as the value at 6 months minus the value at baseline |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Score in Worst Pain Over the Last Month | Baseline, 6 months | score on a scale | MEDIAN | |
| SECONDARY | Changes in Pain Interference Scores | Baseline, 6 months | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Score in Worst Pain Over the Last Month | Norethindrone Acetate 5 mg | -0.5 | Standard Deviation 1.5 | score on a scale | |
| Change in Score in Worst Pain Over the Last Month | Cabergoline 0.5 mg | -5 | Standard Deviation 2.5 | score on a scale | |
| Changes in Pain Interference Scores | Norethindrone Acetate 5 mg | 0.85 | Standard Error 1.1 | units on a scale | |
| Changes in Pain Interference Scores | Cabergoline 0.5 mg | 0 | Standard Error 1.1 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Norethindrone Acetate 5 mg Daily | 5 | |
| Overall Study | STARTED | Cabergoline 0.5 mg Twice Weekly | 5 | |
| Overall Study | COMPLETED | Norethindrone Acetate 5 mg Daily | 3 | |
| Overall Study | COMPLETED | Cabergoline 0.5 mg Twice Weekly | 4 | |
| Overall Study | NOT COMPLETED | Norethindrone Acetate 5 mg Daily | 2 | |
| Overall Study | NOT COMPLETED | Cabergoline 0.5 mg Twice Weekly | 1 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | IRREGULAR VAGINAL BLEEDING | Reproductive system and breast disorders | Control | 2 | 4 | 2 |
| other | IRREGULAR VAGINAL BLEEDING | Reproductive system and breast disorders | Experimental | 2 | 5 | 3 |
| other | NAUSEA | Gastrointestinal disorders | Control | 1 | 4 | 1 |
| other | NAUSEA | Gastrointestinal disorders | Experimental | 5 | 5 | 5 |
| other | FATIGUE | General disorders | Control | 1 | 4 | 1 |
| other | FATIGUE | General disorders | Experimental | 2 | 5 | 5 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Control | 0 | 4 |
| Total, all-cause mortality | Experimental | 0 | 5 |
| Total, other adverse events | Control | 4 | 4 |
| Total, other adverse events | Experimental | 5 | 5 |
| Total, serious adverse events | Control | 0 | 4 |
| Total, serious adverse events | Experimental | 0 | 5 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 34934987 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Experimental vs Control: deaths from any cause | Trial comparisons |
| Experimental vs Control: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02542410
GET https://conductscience.org/api/trials/v1/NCT02542410/registered